Skip to main content
. Author manuscript; available in PMC: 2019 Dec 28.
Published in final edited form as: J Control Release. 2018 Oct 9;292:256–276. doi: 10.1016/j.jconrel.2018.10.008

Fig. 10.

Fig. 10.

Schematic of neoantigen selection and personalized cancer vaccine formulation. The mutated antigens are selected by whole-exome sequencing, RNA sequencing, and HLA typing. The selected epitopes are synthesized and formulated with other immunomodulators, yielding personalized cancer vaccines. Adapted from [124]. Reprinted with permission from Nature Publishing Group.